| Emilia A Ploplys, | |
|
400 13th Ave S, Suite 103, Great Falls, MT 59405-4300 | |
| (406) 731-8888 | |
| (406) 731-8876 |
| Full Name | Emilia A Ploplys |
|---|---|
| Gender | Female |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 22 Years |
| Location | 400 13th Ave S, Great Falls, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558475921 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | 11695 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Benefis Hospitals Inc | Great falls, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Benefis Hospitals Inc | 1153235296 | 279 |
News Archive
Infants below the age of one may be too young to get the chicken pox vaccine but far fewer of them got the itchy rash after the U.S. started routinely vaccinating older children in 1995, according to a new study.
Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
University of Rochester optics professor Jannick Rolland has developed an optical technology that provides unprecedented images under the skin's surface.
‘Tis the season for celebrating with family and friends - and searching for those perfect gifts. CIGNA suggests adding another item to the top of the holiday "To Do" list: Be sure to take needed medications to stay healthy this holiday season and into the New Year.
AstraZeneca today announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca's investigational drug, vandetanib, for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer (MTC).
› Verified 1 days ago
| Entity Name | Benefis Hospitals Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780968974 PECOS PAC ID: 1153235296 Enrollment ID: O20100629000044 |
News Archive
Infants below the age of one may be too young to get the chicken pox vaccine but far fewer of them got the itchy rash after the U.S. started routinely vaccinating older children in 1995, according to a new study.
Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
University of Rochester optics professor Jannick Rolland has developed an optical technology that provides unprecedented images under the skin's surface.
‘Tis the season for celebrating with family and friends - and searching for those perfect gifts. CIGNA suggests adding another item to the top of the holiday "To Do" list: Be sure to take needed medications to stay healthy this holiday season and into the New Year.
AstraZeneca today announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca's investigational drug, vandetanib, for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer (MTC).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emilia A Ploplys, Po Box 6010, Great Falls, MT 59406-6010 Ph: (406) 731-8888 | Emilia A Ploplys, 400 13th Ave S, Suite 103, Great Falls, MT 59405-4300 Ph: (406) 731-8888 |
News Archive
Infants below the age of one may be too young to get the chicken pox vaccine but far fewer of them got the itchy rash after the U.S. started routinely vaccinating older children in 1995, according to a new study.
Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
University of Rochester optics professor Jannick Rolland has developed an optical technology that provides unprecedented images under the skin's surface.
‘Tis the season for celebrating with family and friends - and searching for those perfect gifts. CIGNA suggests adding another item to the top of the holiday "To Do" list: Be sure to take needed medications to stay healthy this holiday season and into the New Year.
AstraZeneca today announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca's investigational drug, vandetanib, for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer (MTC).
› Verified 1 days ago